Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genmab ( (GMAB) ) has provided an announcement.
Genmab A/S, the Copenhagen-based biotechnology group specializing in antibody therapies for cancer and other serious illnesses, has spent more than 25 years building a global footprint across North America, Europe and Asia Pacific. Its platform spans multiple next-generation antibody modalities and supports a growing late-stage clinical pipeline alongside eight already approved medicines.
At the annual general meeting on March 19, 2026, shareholders approved a reduction of Genmab’s share capital by a nominal DKK 1.9 million through cancellation of 1.9 million treasury shares. The capital reduction, registered with the Danish Business Authority on April 17, 2026, lowers the total nominal share capital to DKK 62,350,721, a move that marginally increases ownership concentration for remaining shareholders and signals continuing active capital management by the company.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company has built a diversified portfolio of antibody-based formats, including bispecifics, antibody–drug conjugates and immune-modulating antibodies, and its science underpins eight approved antibody therapies worldwide.
Average Trading Volume: 1,641,098
Technical Sentiment Signal: Hold
Current Market Cap: $17.9B
See more data about GMAB stock on TipRanks’ Stock Analysis page.